Syndevrx
Clinical-stage biotechnology company focused on developing polymer‑drug conjugate inhibitors of MetAP2 as a metabo‑oncology therapeutic modality. The company conducts translational research, multicenter early‑phase clinical trials (combination studies), preclinical program development using obesity‑accelerated and PDX models, and collaborations with academic and clinical partners.
Industries
Nr. of Employees
medium (51-250)
Syndevrx
Cambridge, Massachusetts, United States, North America
Patents
Polymer-conjugated METAP2 inhibitors, and therapeutic methods of use thereof
US-10722532-B2
View Details
Polymer-conjugated METAP2 inhibitors, and therapeutic methods of use thereof
US-10722532-B2
View DetailsProducts
Polymer‑conjugated MetAP2 inhibitor (clinical candidate)
Investigational polymer‑small molecule conjugate designed to combine anti‑angiogenic and metabolic‑hormone‑modulating activities while altering biodistribution and release kinetics to reduce systemic exposure and enable combination use with standard‑of‑care oncology agents.
Polymer‑conjugated MetAP2 inhibitor (clinical candidate)
Investigational polymer‑small molecule conjugate designed to combine anti‑angiogenic and metabolic‑hormone‑modulating activities while altering biodistribution and release kinetics to reduce systemic exposure and enable combination use with standard‑of‑care oncology agents.
Services
Case‑by‑case physician‑initiated requests for access to an investigational oncology therapy for eligible patients outside of clinical trials; decisions depend on drug supply, physician assessment, and company resources.
Sponsorship and operational support for multicenter oncology clinical trials, including protocol execution, site partnerships, and integration of translational biomarker endpoints.
Case‑by‑case physician‑initiated requests for access to an investigational oncology therapy for eligible patients outside of clinical trials; decisions depend on drug supply, physician assessment, and company resources.
Sponsorship and operational support for multicenter oncology clinical trials, including protocol execution, site partnerships, and integration of translational biomarker endpoints.
Expertise Areas
- Metabo‑oncology (metabolic drivers of cancer)
- Early‑phase clinical trial management and combination study design
- Polymer‑drug conjugates and CMC for small molecules
- Translational pharmacology and biomarker‑driven development
Key Technologies
- MetAP2 inhibition
- Polymer‑drug conjugation
- Anti‑angiogenic therapeutic approaches
- Metabolic‑hormone modulation (insulin, leptin, adiponectin)
News & Updates
Interim clinical data from an ongoing Phase 1b/2 combination study of a polymer‑conjugated MetAP2 inhibitor with PI3K/AKT pathway inhibitors in HR+/HER2− metastatic breast cancer to be presented at ASCO 2026.
Safety run‑in cohort results showing anti‑tumor activity and systemic metabolic biomarker improvements from a combination study of a polymer‑conjugated MetAP2 inhibitor plus eribulin in metastatic TNBC patients.
Planned Phase 2a pilot study evaluating a MetAP2 inhibitor in aggressive variant/neuroendocrine phenotype metastatic prostate cancer opening to accrual at specified Australian hospitals.
Regular presentation of preclinical and clinical data at major conferences including AACR, SABCS, ESMO and Prostate Cancer Foundation meetings covering prostate cancer models, obesity‑accelerated cancer models, PK/PD and clinical safety data.
Peer‑reviewed publication reporting anti‑tumor and systemic metabolic improvements of a polymer‑conjugated MetAP2 inhibitor in preclinical models of obesity‑accelerated cancer.
Peer‑reviewed article describing physicochemical and pharmacological characterization of a polymer‑drug conjugate MetAP2 inhibitor.
Interim clinical data from an ongoing Phase 1b/2 combination study of a polymer‑conjugated MetAP2 inhibitor with PI3K/AKT pathway inhibitors in HR+/HER2− metastatic breast cancer to be presented at ASCO 2026.
Safety run‑in cohort results showing anti‑tumor activity and systemic metabolic biomarker improvements from a combination study of a polymer‑conjugated MetAP2 inhibitor plus eribulin in metastatic TNBC patients.
Planned Phase 2a pilot study evaluating a MetAP2 inhibitor in aggressive variant/neuroendocrine phenotype metastatic prostate cancer opening to accrual at specified Australian hospitals.
Regular presentation of preclinical and clinical data at major conferences including AACR, SABCS, ESMO and Prostate Cancer Foundation meetings covering prostate cancer models, obesity‑accelerated cancer models, PK/PD and clinical safety data.
Peer‑reviewed publication reporting anti‑tumor and systemic metabolic improvements of a polymer‑conjugated MetAP2 inhibitor in preclinical models of obesity‑accelerated cancer.
Peer‑reviewed article describing physicochemical and pharmacological characterization of a polymer‑drug conjugate MetAP2 inhibitor.